Trump's 'Most Favored Nation' Drug Pricing
Analysis based on 6 articles · First reported May 11, 2025 · Last updated May 12, 2025
The proposed executive order by Donald Trump to implement 'most favored nation' pricing for prescription drugs is expected to significantly impact the Pharmaceutical industry, potentially leading to substantial revenue reductions for drugmakers. While this could result in considerable savings for consumers and the United States — Medicare program in the United States, it is viewed negatively by pharmaceutical companies and their lobbying groups like the Pharmaceutical Research and Manufacturers of America, who anticipate adverse effects on their profitability and innovation.
Donald Trump announced his intention to sign an executive order to implement a 'most favored nation' policy for prescription drug pricing in the United States. This policy aims to reduce US prescription drug costs by 30% to 80%, aligning them with the lowest prices paid by other high-income countries. The announcement was made on Truth Social, with the order expected to be signed on Monday. This initiative is anticipated to focus on the United States — Medicare health insurance program and expand beyond the scope of price negotiations under Joe Biden's Inflation Reduction Act. The Pharmaceutical Research and Manufacturers of America, through its spokesperson Alex Schriver, has expressed strong opposition, arguing that 'Government price setting in any form is bad for American patients'. This is not Donald Trump's first attempt at such a policy; a similar proposal during his first term was blocked by a court, which had projected over $85 billion in taxpayer savings over seven years.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard